Med BioGene Gets Additional Investment from SEP Capital | GenomeWeb

NEW YORK (GenomeWeb News) – Med BioGene today said that it has signed an agreement with SEP Capital to sell nearly C$500,000 (US$434,000) in units to the investment firm in a private placement.

The deal comes on the heels of Med BioGene raising C$1.6 million through a private placement last month of 20 million units in two tranches. The Vancouver, BC-based molecular diagnostics firm said that SEP will invest all of its available cash reserves — C$475,979 as of Dec. 31, 2008 — in the placement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The White House has created a list of cuts, including to the NIH, that could be in a budget bill for this year.

The US National Institutes of Health is to allow applicants to cite preprints just as they would any other research paper, ScienceInsider reports.

Two manuscript pages handwritten by Charles Darwin are going on the auction block, according to the Los Angeles Times.

In PNAS this week: tool to track transcriptome-wide binding, evidence of balancing selection on behavior-linked genes, and more.